Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIOGAIA AB currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units. Each pending action is being reviewed by a different examiner in a different art unit, which may lead to varied prosecution timelines and outcomes based on the specific practices of each unit.
The busiest examiner, HINES, JANA A, is responsible for 1 pending office action. Given that there are 3 distinct examiners for the 3 pending actions, no single examiner holds a majority of the portfolio's active workload. This structure requires the applicant to manage 3 separate examiner relationships across 3 specialized art units to resolve the current pending actions. The presence of 3 distinct art units indicates that the company's 3 pending office actions involve different biological or pharmaceutical methodologies.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HINES, JANA A | 1 | 53.0% | +39.7% |
| CURRENS, GRANT CARSON | 1 | 54.6% | +62.5% |
| VAN BUREN, LAUREN K | 1 | 39.8% | +58.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18060626 | HISTAMINE-PRODUCING BACTERIAL STRAINS AND THEIR USE IN CANCER | VAN BUREN, LAUREN K | 51d overdue |
| 18002670 | PROBIOTIC COMPOSITION FOR TOPICAL USE | CURRENS, GRANT CARSON | 33d |
| 18510979 | Therapeutic Microvesicles of Probiotic Bacteria | HINES, JANA A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1651 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18510979 | Therapeutic Microvesicles of Probiotic Bacteria | HINES, JANA A | 1645 | §103 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18002670 | PROBIOTIC COMPOSITION FOR TOPICAL USE | CURRENS, GRANT CARSON | 1651 | §103 | Final Rejection | 33d | Pending | Dec 21, 2022 |
| 18060626 | HISTAMINE-PRODUCING BACTERIAL STRAINS AND THEIR USE IN CANCER | VAN BUREN, LAUREN K | 1638 | §103 | Final Rejection | 51d overdue | Pending | Dec 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial